(Q38529439)

3 September 2017

1 reference

title

Why have ovarian cancer mortality rates declined? Part I. Incidence (English)

1 reference

3 September 2017

1 reference

4

Steven A Narod

1 reference

3 September 2017

Victoria Sopik

1

1 reference

3 September 2017

Javaid Iqbal

series ordinal

2

1 reference

3 September 2017

Barry Rosen

series ordinal

3

1 reference

3 September 2017

language of work or name

English

0 references

publication date

13 June 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

138

1 reference

3 September 2017

issue

3

1 reference

3 September 2017

page(s)

741-749

1 reference

3 September 2017

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Tumor characteristics and clinical outcome of elderly women with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Adherence to treatment guidelines for ovarian cancer as a measure of quality care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Women's trials: the approval of the first oral contraceptive pill in the United States and Great Britain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Effect of Screening on Ovarian Cancer Mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Ovarian carcinoma diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Delay in diagnosis of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

The fallopian tube: primary site of most pelvic high-grade serous carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Factors associated with undergoing bilateral salpingo-oophorectomy at the time of hysterectomy for benign conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Bilateral oophorectomy trends in Olmsted County, Minnesota, 1950-1987.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Prophylactic bilateral oophorectomy or removal of remaining ovary at the time of hysterectomy in the United States, 1979-2004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Ovarian cancer rates after hysterectomy with and without salpingo-oophorectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Ovarian cancer risk after salpingectomy: a nationwide population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Trends in bilateral oophorectomy at the time of hysterectomy for benign disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

ACOG Practice Bulletin No. 89. Elective and risk-reducing salpingo-oophorectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Hormone replacement therapy and ovarian cancer risk: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Genital powder use and risk of ovarian cancer: a pooled analysis of 8,525 cases and 9,859 controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Breastfeeding and ovarian cancer risk: a meta-analysis of epidemiologic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

Declining ovarian cancer rates in U.S. women in relation to parity and oral contraceptive use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.017

10.1016/J.YGYNO.2015.06.017

7 January 2021

Identifiers

DOI

1 reference

3 September 2017

1 reference